Term
|
Definition
MOA: selectively inhibits cholesterol uptake through a brush border protein (NPC1L1)
INDICATION: hyperlipidemia
PHARM EFFECTS: dec cholesterold absorption by 50%; dec LDL concentration in the plasma; dec cholesterol content of chylomicrons
ADVERSE EFECTS: abdominal pain, diarrhea
CONTRAINDICATIONS: hepatic impairment |
|
|
Term
fenofibrate (TriCor)
gemfibrozil (Lopid) |
|
Definition
MOA: PPARa agonist (binds to PPARa, a transcription factor controlling expression of lipid-metabolizing enzymes)
INDICATION: hyperlipidemia
PHARM EFFECTS: inc muscle expression of lipoprotein lipase, inc uptake of TG-containing lipoproteins; inc HDL; dec TGs
CONTRAINDICATIONS: warfarin (fibric acid derivatives displace warfarin from its albumin binding site) |
|
|
Term
|
Definition
MOA: inhibition of acyl-CoA acyltransferase, inc mitochondrial & peroxisomal b-oxidation in liver, dec lipogenesis in liver, and inc plasma lipoprotein lipase activity
INDICATION: hyperlipidemia |
|
|
Term
|
Definition
MOA: non-absorbed polymer which sequesters bile acids in the intestines so that they are not reabsorbed
INDICATION: hyperlipidemia, ADJUNCT w/ statins
PHARM EFFECTS: inc conversion of cholesterol to bile acids; inc clearance of plasma LDL-cholesterol
Boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia
Adjunct with statins |
|
|
Term
albuterol (Proventil)
salmeterol |
|
Definition
MOA: B2 adrenergic receptor agonist;
acts via G-protein-coupled receptor, ultimately leading to an efflux of Ca++ from intracellular compartment --> dec myosin light chain relaxation --> bronchodilation
INDICATION:
SHORT-ACTING - albuterol --> used for acute bronchospasm relief;
LONG-ACTING salmeterol --> used as a controller for asthma (long-term control of bronchospasm)
PHARM EFFECTS: dec inflammatory cytokine production, dec in responsiveness of airway to inflammatory mediators, dec plasma exudation
ADVERSE EFECTS: w/ long-term use, inc asthma exacerbations, loss of bronchoprotection |
|
|
Term
|
Definition
PHARM EFFECTS: dec accumulation of macrophages and leukocytes; dec phagocytosis; dec lysosomal enzyme release; dec release of chemical mediators of inflammation
ADVERSE EFECTS: oropharyngeal candidiasis, dysphonia, leads to decreased adherence and quality of life |
|
|
Term
|
Definition
MOA: inhibition of phosphodiesterase; direct histone deacetylase activation
INDICATION: asthma
PHARM EFFECTS: bronchodilation; anti-inflammatory effects --> dec mediator release from inflammatory cells, dec allergen response
ADVERSE EFECTS: nausea, vomiting, headache, insomnia; overdose: persistent vomiting, cardiac arrythmias, & intractable seizures which can be lethal |
|
|
Term
|
Definition
MOA: competitive antagonist of cysteinyl leukotriene receptor
INDICATION: asthma & seasonal allergy rhinitis
CONTRAINDICATIONS: ASA & NSAIDs |
|
|
Term
|
Definition
MOA: inhibits 5-lipoxygenase
INDICATION: prophylaxis & chronic treatment of asthma
ADVERSE EFECTS: can cause liver problems --> must monitor liver enzymes during therapy |
|
|
Term
|
Definition
MOA: anti-IgE monoclonal antibody
ADVERSE EFECTS: nasopharyngitis, upper respiratory infection, headache; rare anaphylaxis reaction
"mab" Monoclonal AntiBody |
|
|
Term
ipratropium (Atrovent)
tiotropium (Spiriva) |
|
Definition
MOA: competitive antagonism of acetylcholine at M3 receptors in the lung
ADVERSE EFECTS: dry mouth, altered taste & coughing after administration |
|
|
Term
| Diuretic potency greatest to least |
|
Definition
| loop (furosemide), thiazide, potassium sparing (spironolactone) |
|
|
Term
| Spironolactone (Aldactone) |
|
Definition
aldosterone antagonist and potassium sparing diuretic
-It prevents the nuclear translocation of the mineralocorticoid receptor.
-Indications
Hypertension
Edema states
Heart failure
Hepatic cirrhosis
Congestive Heart Failure
Hypokalemia
Male to female gender transformation
- decrease anti hypertension with NSAIDs
Spirono"lactate" = lactate, man boobs, gender transformation |
|
|
Term
|
Definition
|
|
Term
| Hydrochlorothiazide (HCTZ) |
|
Definition
Mechanism: Binds to the Na+Cl- cotransporter in the distal tubule and inhibits turnover
MOA: binds to the NaCl cotransporter in the distal tubule and inhibits turnover
INDICATION: HTN, edema (CHF, hepatic cirrhosis, renal dysfunction, corticosteroid therapy)
PHARM EFFECTS: dec in NaCl reabsorption, inc absorption of Ca++
ADVERSE EFECTS: hypokalemia, hyponatremia, gout, dry mouth, lichenoid rxns, orhtostatic hypotension
CONTRAINDICATIONS: NSAIDs -- dec anti-HTN effect
opiates -- inc orthostatic hypotension |
|
|
Term
|
Definition
MOA: inhibition of NaCl reabsorption in loop of Henle by binding to Cl- site of cotransporter
INDICATION: HTN, heart failure, acute pulmonary edema, hyperkalemia, hypercalcemia, edema states
PHARM EFFECTS: reduces extracellular fluid volume and BP with a greater magnitude than with thiazides
ADVERSE EFECTS: same as those for thiazides with respect to hypokalemia and hyponatremia
CONTRAINDICATIONS: NSAIDs -- dec anti-HTN effect |
|
|
Term
| Diuretics main dental concerns: |
|
Definition
| Dry Mouth, lichenoid rxs, orthostatic hypotension |
|
|
Term
|
Definition
MOA: binds & activates guanylyl cyclase in endothelial cells
greatly decreases preload
INDICATION: acute chest pain
PHARM EFFECTS: relaxation of vascular smooth muscle leading to vasodilation and dec BP
ADVERSE EFECTS: headache, orthostatic hypotension, stroke, dizziness, reflex tachycardia,
CONTRAINDICATIONS: opiates -- inc effects of NO |
|
|
Term
| Which Ca channel blocker that can be used with beta blockers? |
|
Definition
|
|
Term
| Which Ca channel blockers are contraindicated with beta blockers? |
|
Definition
verapamil (Calan)
dilitazem (Cardizem) |
|
|
Term
|
Definition
Positive ionotrope
effects contractility
Inhibition of the sodium-potassium ATPase
in available sodium
↓ the rate of calcium-sodium exchange
More calcium is available for contraction of cardiac muscle
↑ force of contraction
↓ rate of contraction
Heart pumps more efficiently
metabolized by gut bacteria, can have a problem if pt is on antibiotics leading to digoxin toxicity --
Signs of toxicity
Excessive salivation
Headache
Fatigue and drowsiness
Abdominal pain
Visual disturbances Yellow or green haze around objects |
|
|
Term
| Most common heart rhythm disturbance |
|
Definition
|
|
Term
|
Definition
MOA: alteration of the lipid membrane in which channels are receptors are located
PHARM EFFECTS: lengthens refractory period by inhibiting K+ channels, blocks Na+ & Ca++ channels, antagonizes a & b adrenergic receptors |
|
|
Term
| Dental Management Precautions with hypertension |
|
Definition
Avoid the use of epinephrine-impregnated gingival retraction cord
Avoid the use of vasoconstrictors for direct hemostasis to control local bleeding
Avoid stimulating the gag reflex in patients with a history of hypertension |
|
|
Term
|
Definition
Thiazide diuretics
β blockers |
|
|
Term
Amlodipine (Norvasc)/ Ramipril (Altace)
Why is this an efficacious therapeutic combination? |
|
Definition
Baroreceptor reflexes
↑sympathetic outflow
Tachycardia
Increased contractility
Vasoconstriction
Renal perfusion reflexes
↑Renin release
you are able to block the compensatory changes associated with the baroreceptor reflex, so when rein increases you inhibit that Angiotensin/Aldosterone cycle. |
|
|
Term
|
Definition
MOA: binds AP-1 or NK-kB intraceullar transcription factors to inhibit their pro-inflammatory action; inc expression of glucocorticoid-induced leucine zipper proteins; chromatin remodeling
INDICATION: chronic inflammatory and immune diseases (see list at right)
PHARM EFFECTS: inhibition of accumulation of macrophages and leukocytes, phagocytosis, lysosomal enzyme release, and release of chemical mediators of inflammation
NOTES: withdrawal syndrome (requires 3 day tapering period for all courses of therapy) --> joint pain, muscle pain, fatigue, fever, nausea & vomiting may cause acute adrenal crisis (low endogenous cortisol) with chronic therapy -- low BP, dehydration, confusion, tachypnea, sweating, shock, coma, seizures, delays wound healing |
|
|
Term
| prednisone adverse effects |
|
Definition
Dermatologic:
impaired and delayed wound healing
Thin fragile skin
Neurologic:
Convulsions
Vertigo
Headache
Endocrine:
Development of Cushing's state
Secondary adrenocortical and pituitary unresponsiveness
Diabetes
Fluid and Electrolyte:
Sodium and fluid retention
CHF, HTN and potassium loss
Musculoskeletal:
Loss of muscle mass
Osteoporosis
Compression fractures
GI:
Peptic ulcer
Pancreatitis
Ulcerative esophagitis |
|
|
Term
|
Definition
MOA: folate analog which inhibits endogenous folate synthesis --> apoptosis of CD4 & CD8 T cells
INDICATION: rheumatoid arthritis, psoriasis, graft vs. host disease, severe asthma
PHARM EFFECTS: anti-inflammatory effects
ADVERSE EFECTS: leukopenia
NOTES: once-per-week dosing |
|
|
Term
| mycophenolate mofetil (CellCept) |
|
Definition
MOA: inhibitor of inosine monophosphate dehydrogenase (rate limiting enzyme in biosynthesis of guanosine)
INDICATION: not listed, but presumably the same as methotrexate's?
PHARM EFFECTS: induces activated T cell apoptosis, dec lymphocyte activation and activity, dec expression of adhesion molecules, dec production of NO by neutrophils
ADVERSE EFECTS: mout ulceration, gingival hyperplasia, gingivitis, dry mouth, dysphagia |
|
|
Term
cyclosporine
tacrolimus (Prograf) |
|
Definition
MOA: inhibits synthesis of IL-2 (responsible for activation and proliferation of activated lymphocytes) in activated T cells
INDICATION: immunosuppressant for graft survival, topical for oral lichen planus, psoriasis, rheumatoid arthritis, chronic dry eyes
ADVERSE EFECTS: renal toxicity, HTN, hyperlipidemia, neurotoxicity, gingival hyperplasia |
|
|
Term
|
Definition
MOA: inverse agonist which stiblizes the inactive conformation of H1 histamine receptor; some are competitive inhibitors of H2 histamine receptor
INDICATION: DENTISTRY: conscious sedation, pre-med for general anesthesia, reduction of post-op nausea, allergic lesions of oral mucosa; OTHER: nasal allergies, symptomatic relief of common cold, motion sickness, sedation
PHARM EFFECTS: H1 blockage: anti-inflammatory effects; H2 blockage: anti-emetic effects (e.g. Phenergan)
ADVERSE EFECTS: CNS depression --> drowsiness, lethargy, dec motor coordination; anti-muscarinic effects --> dry mouth, constipation, blurred vision |
|
|
Term
| 1st GENERATION antihistamines |
|
Definition
diphenhydramine (Benadryl)
chlorpheniramine (Chlor-Trimeton)
meclizine (Antivert)
for vertigo
promethazine (Phenergan)
for nausea & vomiting |
|
|
Term
| 2nd GENERATION antihistamines (less CNS depression than what is seen in 1st generation) |
|
Definition
loratadine (Claritin)
fexofenadine (Allegra)
cetirizine (Zyrtec) |
|
|
Term
|
Definition
MOA: binds to and inactivates TNFa (cytokine which enables normal inflammatory and immune responses)
INDICATION: autoimmune diseases: rheumatoid arthritis, ulcerative colitis, Crohn's disease, psoriasis
PHARM EFFECTS: immunosuppression
ADVERSE EFECTS: inc susceptibility to opportunistic infections, inc risk for TB, invasive fungal infections, sepsis, CNS demyelination |
|
|
Term
|
Definition
MOA: IL-2 receptor antagonist
INDICATION: autoimmune diseases: rheumatoid arthritis, ulcerative colitis, Crohn's disease, psoriasis
PHARM EFFECTS: inhibits IL-2 activation of lymphocytes
ADVERSE EFECTS: inc susceptibility to opportunistic infections |
|
|
Term
|
Definition
MOA: arrests mitosis in metaphase by binding to microtubular protein and preventing spindle formation, inhibits neutrophil migration and phagocytic activity in inflamed joints, inhibits inflammatory response by inhibiting neutrophil activation
INDICATION: gout
PHARM EFFECTS: dec trafficking of phagocytosed particles to lysosomes, dec release of chemotactic factors, dec motility and adhesion of neutrophils, phosphorylation of neutrophil proteins
ADVERSE EFECTS: neutropenia, diarrhea
NOTES: to treat gout, red meat is eliminated from the diet, and NSAIDs + colchicine for first 4-6 months to prevent acute episodes during beignning of chronic therapy |
|
|
Term
|
Definition
MOA: non-competitive inhibitor of xanthene oxidase
INDICATION: chronic gout
PHARM EFFECTS: dec biosynthesis of uric acid |
|
|
Term
|
Definition
MOA: inhibits the basolateral anion exchanger of
PHARM EFFECTS: dec [urate] in plasma
ADVERSE EFECTS: may develop urate stones in kidney or ureter, gingival soreness, nausea+vomiting, dizziness |
|
|
Term
|
Definition
MOA: soluble TNF receptor dimer-Fc fusion protein
Rheumatoid arthritis |
|
|
Term
|
Definition
MOA: monoclonal antibodies consisting of the ligand binding portion of the TNFa receptor
Rheumatoid arthritis |
|
|
Term
| Proposed Roles for Tumor Necrosis Factor in Rheumatoid Arthritis |
|
Definition
Cytokine
Central to many aspects of the inflammatory response
Stimulates macrophages to secrete phagocytic compounds
Stimulates production of acute phase proteins |
|
|
Term
|
Definition
Drug Therapy:
Acetaminophen
NSAIDS
Duloxetine (Cymbalta)-approved indication
Glucosamine/Condroitin sulfates
Intra-articular hyaluronic acid injections
Joint replacement surgery |
|
|
Term
|
Definition
-imbalances in purine metabolism
-Purines are metabolized to uric acid, which is barely soluble in plasma
-Normal uric acid levels are 4-6 mg/dL
-Plasma levels above 6.8 mg/dL is saturation |
|
|
Term
|
Definition
Infliximab (Remicade)
Etanercept (Enbrel)
Methotrexate |
|
|
Term
|
Definition
NSAIDS
Steroids
Colchicine
Allopurinol
Probenecid |
|
|
Term
|
Definition
Acetaminophen
NSAIDS
Duloxetine
Glucosamine/Condroitin sulfates |
|
|
